Atherosclerosis Therapeutics Development Pipeline Review, H2 2015 - Research and Markets

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/jl36n2/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Atherosclerosis Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis Prostate Cancer and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Atherosclerosis Prostate Cancer Overview
3. Therapeutics Development
4. Pipeline Products for Atherosclerosis Prostate Cancer - Overview
5. Pipeline Products for Atherosclerosis Prostate Cancer - Comparative Analysis
6. Atherosclerosis Prostate Cancer - Therapeutics under Development by Companies
7. Atherosclerosis Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
8. Atherosclerosis Prostate Cancer - Pipeline Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Atherosclerosis Prostate Cancer - Products under Development by Companies
13. Atherosclerosis Prostate Cancer - Products under Investigation by Universities/Institutes
14. Atherosclerosis Prostate Cancer - Companies Involved in Therapeutics Development

• Ache Laboratorios Farmaceuticos S/A
• advanceCor GmbH
• AFFiRiS AG
• Arisaph Pharmaceuticals, Inc.
• Artery Therapeutics, Inc.
• AstraZeneca Plc
• Athera Biotechnologies AB
• AtheroNova Inc.
• Bayer AG
• Campus Technologies Freiburg GmbH
• Cardax Pharmaceuticals, Inc.
• Cerenis Therapeutics Holding SA
• ChemoCentryx, Inc.
• CohBar, Inc.
• Daiichi Sankyo Company, Limited
• DoNatur GmbH
• Dybly AG
• Exicure, Inc.
• F. Hoffmann-La Roche Ltd.
• GenKyoTex S.A.
• Gilead Sciences, Inc.
• Jenrin Discovery, Inc.
• Johnson & Johnson
• KineMed, Inc.
• Kowa Company, Ltd.
• La Jolla Pharmaceutical Company
• Lead Discovery Center GmbH
• Merck & Co., Inc.
• MI.TO. Technology S.r.L.
• Omeros Corporation
• OPKO Health, Inc.
• Otsuka Holdings Co., Ltd.
• Provid Pharmaceuticals, Inc.
• Resverlogix Corp.

For more information visit http://www.researchandmarkets.com/research/jl36n2/atherosclerosis

View source version on businesswire.com: http://www.businesswire.com/news/home/20160208005562/en/